Internship
Arrowhead Pharmaceuticals
501-1,000 employees
Develops RNAi-based therapies for diseases
No salary listed
San Diego, CA, USA
Upload your resume to see how it matches 12 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
- Currently enrolled student at an Accredited University or College and majoring in information technology, computer science, computer engineering, information technology management or a related field
- Excellent verbal and written communication skills
- Strong problem-solving skills
- Eagerness to learn new techniques.
- Research Analytics: Generate reports and visualizations using data from Arrowheads RNA Data Platform to provide crucial insights and actionable metrics for R&D. This role may involve directly gathering requirements from the user base
- Instrument Asset Management Platform: Enhance and update the existing platform based on user requirements, with occasional involvement in gathering requirements directly from the user base to ensure optimal functionality
Arrowhead Pharmaceuticals develops medicines aimed at treating severe diseases by targeting and silencing the genes responsible for them. The company uses RNA interference (RNAi), a natural process that reduces the expression of specific genes, to achieve effective treatment outcomes. This method allows for significant and lasting reductions in the activity of harmful genes, which can help manage or potentially reverse diseases like cystic fibrosis and hepatitis B. Arrowhead stands out from its competitors by focusing specifically on RNAi-based therapies and leveraging a wide range of RNA chemistries and delivery methods. The company aims to meet unmet medical needs by providing new treatment options for genetic disorders, generating revenue through partnerships, licensing agreements, and future sales of approved therapies.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Pasadena, California
Founded
2004
Simplify's Take
What believers are saying
- Arrowhead's collaboration with Sarepta includes a $500M upfront payment for RNA drug development.
- Positive Phase 2 data for plozasiran boosts Arrowhead's credibility in treating hypertriglyceridemia.
- Strategic financing with Sixth Street provides capital to advance Arrowhead's research pipeline.
What critics are saying
- Increased competition from companies like Alnylam may impact Arrowhead's market share.
- Potential regulatory scrutiny could delay Arrowhead's clinical trials for RNAi therapies.
- Reliance on strategic financing may lead to increased debt obligations for Arrowhead.
What makes Arrowhead Pharmaceuticals unique
- Arrowhead uses RNAi to target and silence disease-causing genes effectively.
- The company has a broad portfolio of RNA chemistries for diverse therapeutic applications.
- Arrowhead's strategic partnerships enhance its capabilities in developing innovative RNAi therapies.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
Paid Vacation
Paid Sick Leave
Company News
Mr. Apel joins the company from Walgreens Boots Alliance, where he served as Global Head of Financial Planning and Analysis from 2019 through 2024.
Arrowhead Pharmaceuticals launches FCS patient resources on Rare Disease Day.
New Patient Resource Hub: Arrowhead expands its We'll Get There Soon campaign with the launch of a dedicated patient website, providing education, tools, and support for those living with FCS and extremely high triglycerides
Recently, Arrowhead Pharmaceuticals and Sarepta Therapeutics signed a global licensing and collaboration agreement to develop clinical and preclinical programmes.
Sarepta Therapeutics is putting massive biobucks on the line to work on RNA drugs with Arrowhead, paying out $500 million upfront to find new treatments for rare genetic diseases of the muscle, central nervous system and lung.